UTMD vs NVCR vs HOLX vs INMD

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -6. 2% for InMode Ltd. (INMD). InMode Ltd. (INMD) offers the better valuation at 9. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, InMode Ltd.

(INMD) is the cheapest at 9. 8x versus Hologic, Inc. at 30. 5x. On forward P/E, InMode Ltd. is actually cheaper at 10. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: InMode Ltd. wins at 1. 04x versus Utah Medical Products, Inc. 's 3. 03x — a reasonable growth-adjusted valuation.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +16. 8%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus UTMD's +19. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 373% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Utah Medical Products, Inc. (UTMD) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -6. 2% for InMode Ltd. (INMD). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Utah Medical Products, Inc.

(UTMD) is the more profitable company, earning 29. 3% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 29. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTMD leads at 29. 6% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, InMode Ltd. (INMD) is the more undervalued stock at a PEG of 1. 04x versus Utah Medical Products, Inc. 's 3. 03x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, InMode Ltd. (INMD) trades at 10. 3x forward P/E versus 17. 2x for Hologic, Inc. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 87. 3% to $33. 50.

In this comparison, UTMD (1.

9% yield) pays a dividend. NVCR, HOLX, INMD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Utah Medical Products, Inc.

(UTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 55), 1. 9% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UTMD: +19. 0%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: UTMD is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock; INMD is a small-cap deep-value stock. UTMD pays a dividend while NVCR, HOLX, INMD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.